Aurealis Therapeutics Announces Peer-Reviewed Paper Published from Phase 1 Study of AUP-16 for Non-Healing Diabetic Foot Ulcers
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is proud to announce the publication of its AUP-16 Phase 1 clinical trial results in the peer-reviewed journal Therapeutic Advances in Endocrinology and Metabolism. The scientific paper, titled “Multi-target gene therapy AUP1602-C to improve healing and quality of […]
